Lesuride MPS Chewable Tablet contains Levosulpiride 25 mg, a selective dopamine D2 receptor antagonist primarily used in the management of gastrointestinal motility disorders and certain psychiatric conditions. Levosulpiride exerts prokinetic effects by enhancing gastric emptying and improving esophageal motility, making it effective in treating functional dyspepsia, gastroesophageal reflux disease (GERD), and diabetic gastroparesis. Additionally, its central dopaminergic antagonism contributes to its efficacy in the treatment of depression, anxiety, and schizophrenia, particularly in cases resistant to conventional therapies. The chewable formulation facilitates ease of administration, improving patient compliance, especially in populations with swallowing difficulties. Lesuride MPS is generally well tolerated; however, adverse effects may include extrapyramidal symptoms, hyperprolactinemia, and gastrointestinal disturbances such as nausea and diarrhea. It is contraindicated in patients with hypersensitivity to sulpiride or related compounds, severe renal impairment, and in those with prolactin-dependent tumors. Caution is advised when used concomitantly with other central nervous system depressants or antipsychotics. Dosage should be individualized based on the clinical condition and patient response. Lesuride MPS Chewable Tablet should be used under medical supervision to ensure optimal therapeutic outcomes and minimize potential risks.